NEWS

March 28, 2023
Travere Therapeutics to Present at Upcoming Investor Conferences
March 23, 2023
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
March 14, 2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2023
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
March 3, 2023
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
March 1, 2023
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
February 27, 2023
Travere Therapeutics Announces Proposed Public Offering of Common Stock
February 23, 2023
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
February 17, 2023
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
February 16, 2023
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
February 13, 2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 8, 2023
Travere Therapeutics to Present at Upcoming Investor Conferences